Literature DB >> 23770013

In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling.

Peter G Miller1, Fatima Al-Shahrour, Kimberly A Hartwell, Lisa P Chu, Marcus Järås, Rishi V Puram, Alexandre Puissant, Kevin P Callahan, John Ashton, Marie E McConkey, Luke P Poveromo, Glenn S Cowley, Michael G Kharas, Myriam Labelle, Sebastian Shterental, Joji Fujisaki, Lev Silberstein, Gabriela Alexe, Muhammad A Al-Hajj, Christopher A Shelton, Scott A Armstrong, David E Root, David T Scadden, Richard O Hynes, Siddhartha Mukherjee, Kimberly Stegmaier, Craig T Jordan, Benjamin L Ebert.   

Abstract

We used an in vivo small hairpin RNA (shRNA) screening approach to identify genes that are essential for MLL-AF9 acute myeloid leukemia (AML). We found that Integrin Beta 3 (Itgb3) is essential for murine leukemia cells in vivo and for human leukemia cells in xenotransplantation studies. In leukemia cells, Itgb3 knockdown impaired homing, downregulated LSC transcriptional programs, and induced differentiation via the intracellular kinase Syk. In contrast, loss of Itgb3 in normal hematopoietic stem and progenitor cells did not affect engraftment, reconstitution, or differentiation. Finally, using an Itgb3 knockout mouse model, we confirmed that Itgb3 is dispensable for normal hematopoiesis but is required for leukemogenesis. Our results establish the significance of the Itgb3 signaling pathway as a potential therapeutic target in AML.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23770013      PMCID: PMC3746037          DOI: 10.1016/j.ccr.2013.05.004

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  59 in total

1.  Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors.

Authors:  Antonio Cozzio; Emmanuelle Passegué; Paul M Ayton; Holger Karsunky; Michael L Cleary; Irving L Weissman
Journal:  Genes Dev       Date:  2003-12-15       Impact factor: 11.361

2.  p53 alterations in human leukemia-lymphoma cell lines: in vitroartifact or prerequisite for cell immortalization?

Authors:  H G Drexler; S Fombonne; Y Matsuo; Z B Hu; H Hamaguchi; C C Uphoff
Journal:  Leukemia       Date:  2000-01       Impact factor: 11.528

3.  Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.

Authors:  Mark P Chao; Ash A Alizadeh; Chad Tang; June H Myklebust; Bindu Varghese; Saar Gill; Max Jan; Adriel C Cha; Charles K Chan; Brent T Tan; Christopher Y Park; Feifei Zhao; Holbrook E Kohrt; Raquel Malumbres; Javier Briones; Randy D Gascoyne; Izidore S Lossos; Ronald Levy; Irving L Weissman; Ravindra Majeti
Journal:  Cell       Date:  2010-09-03       Impact factor: 41.582

4.  The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth.

Authors:  Nisha C Kakodkar; Radhika Peddinti; Morris Kletzel; Yufeng Tian; Lisa J Guerrero; Samir D Undevia; David Geary; Alexandre Chlenski; Qiwei Yang; Helen R Salwen; Susan L Cohn
Journal:  Pediatr Blood Cancer       Date:  2011-01       Impact factor: 3.167

5.  Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1.

Authors:  C Liao; X Y Wang; H Q Wei; S Q Li; T Merghoub; P P Pandolfi; D J Wolgemuth
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

6.  Syk is required for integrin signaling in neutrophils.

Authors:  Attila Mócsai; Meijuan Zhou; Fanying Meng; Victor L Tybulewicz; Clifford A Lowell
Journal:  Immunity       Date:  2002-04       Impact factor: 31.745

7.  Signaling through GP Ib-IX-V activates alpha IIb beta 3 independently of other receptors.

Authors:  Ana Kasirer-Friede; Maria Rita Cozzi; Mario Mazzucato; Luigi De Marco; Zaverio M Ruggeri; Sanford J Shattil
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

Review 8.  Integrin signalling during tumour progression.

Authors:  Wenjun Guo; Filippo G Giancotti
Journal:  Nat Rev Mol Cell Biol       Date:  2004-10       Impact factor: 94.444

9.  TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways.

Authors:  T Kanie; A Abe; T Matsuda; Y Kuno; M Towatari; T Yamamoto; H Saito; N Emi; T Naoe
Journal:  Leukemia       Date:  2004-03       Impact factor: 11.528

10.  Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia.

Authors:  Marc H G P Raaijmakers; Siddhartha Mukherjee; Shangqin Guo; Siyi Zhang; Tatsuya Kobayashi; Jesse A Schoonmaker; Benjamin L Ebert; Fatima Al-Shahrour; Robert P Hasserjian; Edward O Scadden; Zinmar Aung; Marc Matza; Matthias Merkenschlager; Charles Lin; Johanna M Rommens; David T Scadden
Journal:  Nature       Date:  2010-03-21       Impact factor: 49.962

View more
  82 in total

1.  Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program.

Authors:  Sun-Mi Park; Mithat Gönen; Ly Vu; Gerard Minuesa; Patrick Tivnan; Trevor S Barlowe; James Taggart; Yuheng Lu; Raquel P Deering; Nir Hacohen; Maria E Figueroa; Elisabeth Paietta; Hugo F Fernandez; Martin S Tallman; Ari Melnick; Ross Levine; Christina Leslie; Christopher J Lengner; Michael G Kharas
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

2.  Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML.

Authors:  Rishi V Puram; Monika S Kowalczyk; Carl G de Boer; Rebekka K Schneider; Peter G Miller; Marie McConkey; Zuzana Tothova; Héctor Tejero; Dirk Heckl; Marcus Järås; Michelle C Chen; Hubo Li; Alfred Tamayo; Glenn S Cowley; Orit Rozenblatt-Rosen; Fatima Al-Shahrour; Aviv Regev; Benjamin L Ebert
Journal:  Cell       Date:  2016-04-07       Impact factor: 41.582

Review 3.  Advances in understanding the leukaemia microenvironment.

Authors:  Yoko Tabe; Marina Konopleva
Journal:  Br J Haematol       Date:  2014-01-09       Impact factor: 6.998

Review 4.  Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

Authors:  Bin E Li; Patricia Ernst
Journal:  Exp Hematol       Date:  2014-09-28       Impact factor: 3.084

Review 5.  Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance.

Authors:  Jonathan Cooper; Filippo G Giancotti
Journal:  Cancer Cell       Date:  2019-03-18       Impact factor: 31.743

6.  Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia.

Authors:  Xin Long; Yang Yu; Laszlo Perlaky; Tsz-Kwong Man; Michele S Redell
Journal:  Br J Haematol       Date:  2015-05-14       Impact factor: 6.998

Review 7.  RNAi screening comes of age: improved techniques and complementary approaches.

Authors:  Stephanie E Mohr; Jennifer A Smith; Caroline E Shamu; Ralph A Neumüller; Norbert Perrimon
Journal:  Nat Rev Mol Cell Biol       Date:  2014-09       Impact factor: 94.444

8.  SYK is a critical regulator of FLT3 in acute myeloid leukemia.

Authors:  Alexandre Puissant; Nina Fenouille; Gabriela Alexe; Yana Pikman; Christopher F Bassil; Swapnil Mehta; Jinyan Du; Julhash U Kazi; Frédéric Luciano; Lars Rönnstrand; Andrew L Kung; Jon C Aster; Ilene Galinsky; Richard M Stone; Daniel J DeAngelo; Michael T Hemann; Kimberly Stegmaier
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

9.  The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia.

Authors:  Hubo Li; Brenton G Mar; Huadi Zhang; Rishi V Puram; Francisca Vazquez; Barbara A Weir; William C Hahn; Benjamin Ebert; David Pellman
Journal:  Blood       Date:  2016-10-18       Impact factor: 22.113

10.  Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors.

Authors:  Pia Riemke; Melinda Czeh; Josephine Fischer; Carolin Walter; Saeed Ghani; Matthias Zepper; Konstantin Agelopoulos; Stephanie Lettermann; Marie L Gebhardt; Nancy Mah; Andre Weilemann; Michael Grau; Verena Gröning; Torsten Haferlach; Dido Lenze; Ruud Delwel; Marco Prinz; Miguel A Andrade-Navarro; Georg Lenz; Martin Dugas; Carsten Müller-Tidow; Frank Rosenbauer
Journal:  EMBO J       Date:  2016-08-29       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.